NATCO Pharma has announced the completion of its acquisition of an additional 13.25 percent equity stake in Adcock Ingram Holdings, a leading South African pharmaceutical and healthcare company.

With the completion of this transaction, NATCO’s shareholding in Adcock Ingram has increased from 35.75 percent to 49 percent. The acquisition was completed through NATCO Pharma South Africa, NATCO’s wholly owned subsidiary in South Africa. The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around INR 1,060 crore at the transaction exchange rate.

The completion of the additional stake acquisition marks another significant milestone in NATCO’s long-term Africa strategy.

NATCO first acquired 35.75 percent in Adcock Ingram through its participation in the Adcock Ingram’s delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025.

Pursuant to that, NATCO’s Board further approved the acquisition of an additional 13.25 percent stake in July 2026, and the transaction has now been completed following the satisfaction of customary closing conditions and regulatory requirements.